These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20124158)

  • 1. Two important determinants may play a role in the success of the FinHer Trial.
    Isik M; Dizdar O; Altundag K
    J Clin Oncol; 2010 Jul; 28(20):e334; author reply e335-6. PubMed ID: 20124158
    [No Abstract]   [Full Text] [Related]  

  • 2. When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009 Mar; 31(1):30-1. PubMed ID: 21054206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
    Metcalfe S; Evans J; Priest G
    N Z Med J; 2007 Jun; 120(1256):U2593. PubMed ID: 17589560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary systemic chemotherapy for breast cancer].
    Takada M; Toi M
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
    Tokudome N; Ito Y
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):318-23. PubMed ID: 16531711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible mechanisms behind taxane-anthracycline sequencing.
    Sahin I; Ararat E; Altundag K
    Lancet Oncol; 2010 Jun; 11(6):514-5. PubMed ID: 20522380
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
    Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of adjuvant chemotherapy for breast cancer].
    Takeuchi H; Okubo K; Fujiuchi N; Saeki T
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):736-41. PubMed ID: 16770090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stratification with respect to hormone receptor and HER 2/neu in the treatment of metastatic breast cancer; sensitivity to taxane].
    Kan N; Mise K; Moriguchi Y; Kodama H
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):53-7. PubMed ID: 17220670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M; Roché H; Delozier T; Canon JL; Romieu G; Bourgeois H; Extra JM; Serin D; Kerbrat P; Machiels JP; Lortholary A; Orfeuvre H; Campone M; Hardy-Bessard AC; Coudert B; Maerevoet M; Piot G; Kramar A; Martin AL; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(36):6129-34. PubMed ID: 19917839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
    Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):1911-3. PubMed ID: 18219850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab treatment in breast cancer.
    Montemurro F; Valabrega G; Aglietta M
    N Engl J Med; 2006 May; 354(20):2186; author reply 2186. PubMed ID: 16707759
    [No Abstract]   [Full Text] [Related]  

  • 16. Breast cancer (metastatic).
    Stebbing J; Glassman R
    Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
    Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
    Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
    N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
    Takada M; Terunuma H; Deng X; Dewan MZ; Saji S; Kuroi K; Yamamoto N; Toi M
    Breast Cancer; 2011 Jan; 18(1):64-7. PubMed ID: 20354831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents--more or less.
    Barrett-Lee P; Ellis P; Bliss J;
    Clin Oncol (R Coll Radiol); 2002 Aug; 14(4):263-6. PubMed ID: 12206635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.